ALX Oncology Holdings Inc. - Common Stock (ALXO)
Frequently Asked Questions About ALX Oncology Holdings Inc. - Common Stock (ALXO)
Has ALX Oncology received any investment or funding?
Yes, ALX Oncology has raised significant funding from various sources, including venture capital and public markets, which has facilitated its research and clinical development efforts.
How can investors stay updated on ALX Oncology?
Investors can stay updated on ALX Oncology by following the company's official website, subscribing to press releases, and monitoring financial news platforms for updates regarding clinical trials, corporate developments, and financial performance.
How does ALX Oncology define its competitive advantage?
ALX Oncology believes its competitive advantage lies in its innovative approach to immune modulation via the CD47 pathway, deep expertise in clinical development, and a robust pipeline of product candidates with potential in multiple cancer indications.
How does ALX148 work?
ALX148 works by binding to the CD47 protein on cancer cells, effectively blocking the 'don't eat me' signal that prevents immune cells from attacking tumors. This mechanism re-engages the immune system to recognize and eliminate cancer cells.
Is ALX Oncology publicly traded?
Yes, ALX Oncology Holdings Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol 'ALXO'. The company’s shares became publicly available following its IPO in 2020.
What are the key focus areas of ALX Oncology's research?
ALX Oncology primarily focuses on developing therapies aimed at harnessing the immune system to treat cancers, particularly through the modulation of the CD47 pathway and its impact on tumor microenvironments.
What are the potential side effects of ALX148?
As with many cancer therapies, ALX148 may have side effects that could include low blood cell counts, fatigue, nausea, and infusion reactions. Ongoing clinical trials are investigating the safety profile and tolerability of ALX148.
What challenges does ALX Oncology face?
ALX Oncology faces various challenges, including the competitive landscape of oncology research, the complexities of clinical trials, regulatory hurdles, and the need to demonstrate the efficacy and safety of its therapies to gain market approval.
What clinical trials is ALX Oncology currently running?
ALX Oncology is actively running multiple clinical trials for ALX148, assessing its safety, tolerability, and effectiveness in patients with different types of cancer. These trials include both monotherapy and combination therapy studies.
What does ALX Oncology Holdings Inc. do?
ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with cancer. The company leverages its proprietary technology to create treatments that harness the body's immune system to combat tumors effectively.
What is the company's approach to corporate governance?
ALX Oncology prioritizes strong corporate governance practices, which include maintaining a diverse and experienced board of directors, adhering to ethical standards, and ensuring transparency in its operations and communications with stakeholders.
What is the company's vision for the future?
ALX Oncology’s vision is to develop groundbreaking immuno-oncology therapies that empower the immune system to fight cancer more effectively, ultimately improving survival rates and quality of life for patients battling cancer.
What is the main product candidate of ALX Oncology?
The main product candidate of ALX Oncology is ALX148, a potential treatment for various oncology indications. ALX148 is designed to enhance anti-tumor immunity by blocking CD47 signaling, which tumors often exploit to evade the immune system.
What is the significance of CD47 in cancer therapy?
CD47 is often overexpressed in cancer cells, allowing tumors to evade immune detection. Targeting CD47 can enhance the immune response to cancer, making it a promising therapeutic target for developing cancer treatments.
What markets does ALX Oncology operate in?
ALX Oncology primarily operates in the United States and is exploring global market opportunities as it develops its therapies and seeks regulatory approvals in various jurisdictions.
What partnerships has ALX Oncology formed?
ALX Oncology has established collaborations with several research institutions and pharmaceutical companies to enhance its clinical development programs and expand the reach of its therapies in oncology.
What types of cancer is ALX148 being tested for?
ALX148 is being tested for various types of cancers, including hematologic malignancies, solid tumors, and other indications, with the aim of expanding treatment options for patients with limited available therapies.
When was ALX Oncology Holdings Inc. founded?
ALX Oncology was founded in 2015, with a mission to improve cancer treatment outcomes through novel immuno-oncology therapies that target and inhibit tumor growth.
Where is ALX Oncology headquartered?
ALX Oncology Holdings Inc. is headquartered in South San Francisco, California. This location places the company in a vibrant biotech hub, facilitating collaboration and innovation within the biotech community.
Who are the founders of ALX Oncology?
ALX Oncology was founded by a team of experienced biotechnology and pharmaceutical professionals, including Dr. A.G. Kambayashi, who brought extensive industry experience and insight to the company's vision and mission.
What is the current price of ALX Oncology Holdings Inc. - Common Stock?
The current price of ALX Oncology Holdings Inc. - Common Stock is 0.4996
When was ALX Oncology Holdings Inc. - Common Stock last traded?
The last trade of ALX Oncology Holdings Inc. - Common Stock was at 2:34 pm EDT on April 4th, 2025
What is the market capitalization of ALX Oncology Holdings Inc. - Common Stock?
The market capitalization of ALX Oncology Holdings Inc. - Common Stock is 20.42M
How many shares of ALX Oncology Holdings Inc. - Common Stock are outstanding?
ALX Oncology Holdings Inc. - Common Stock has 40.87M shares outstanding.